View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
January 14, 2019

miRagen reports positive Phase I cobomarsen data for CTCL and ATLL

miRagen Therapeutics has reported positive updated data from a Phase I trial assessing the safety, tolerability and efficacy of cobomarsen for the treatment of cutaneous T-cell lymphoma (CTCL) and T-cell leukemia / lymphoma (ATLL).

miRagen Therapeutics has reported positive updated data from a Phase I trial assessing the safety, tolerability and efficacy of cobomarsen for the treatment of cutaneous T-cell lymphoma (CTCL) and T-cell leukemia / lymphoma (ATLL).

The data showed that four of eight CTCL patients who received 300mg of intravenous therapy (IV) infusion achieved objective response with greater than four months of durability (ORR4).

In the 300mg IV infusion cohort, miRagen used the same dose and route of administration being used in the ongoing SOLAR Phase II trial that intends to study the safety and efficacy of cobomarsen against zolinza (vorinostat) in patients with CTCL.

Cobomarsen also showed a favourable safety and tolerability profile among the ATLL patients enrolled in the Phase I trial.

“The ATLL clinical data shows that cobomarsen provided sustained disease stabilisation in five patients for up to 13 months.”

No serious adverse events and no documented opportunistic infections were reported during the trial.

Two lymphomatous and two acute ATLL patients who showed a partial response following chemotherapy have maintained their responses when treated with cobomarsen monotherapy.

Half of these patients also remained stable for over a year.

miRagen Therapeutics research and development (R&D) executive vice-president Paul Rubin said: “The ATLL clinical data shows that cobomarsen provided sustained disease stabilisation in five patients for up to 13 months after completing chemotherapy or experimental treatment and an improvement in the levels of normal circulating blood cells.

“In addition, patients did not report any significant side effects attributed to cobomarsen.

“We believe these data are particularly encouraging, as the patients in this study had previously failed on other therapies and the median survival for patients with acute disease typically ranges from four to ten months after diagnosis.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena